How much has Hippocratic AI raised?

Hippocratic AI has more than $270 million reported based on public reporting. 2023: Seed — $50 million, led/backed by General Catalyst and Andreessen Horowitz. 2024: Series A — $53 million, led/backed by Premji Invest and General Catalyst ($500 million valuation reported). 2025: Series B — $141 million, led/backed by Kleiner Perkins ($1.64 billion valuation reported). 2025: Strategic extension — $17 million, led/backed by Strategic healthcare investors (Valuation not disclosed).

Where debt, secondaries, or preferred-equity packages are included in public reporting, they are described as reported rather than converted into common-equity funding.

The disclosed investor base includes General Catalyst and Andreessen Horowitz; Premji Invest and General Catalyst; Kleiner Perkins; Strategic healthcare investors. These investors matter because they indicate whether the company is optimized for venture-scale software growth, capital-intensive deployment, clinical development, or government procurement.

For sellers, investor quality is a useful signal, but procurement timing still depends on budget ownership and integration urgency.

The latest public marker is $1.6 billion reported in 2025. Valuation movement appears tied to progress in healthcare ai agents, public customer/partner proof, and the broader investor appetite for AI-enabled category leaders.

No public source confirms profitability, so valuation should be treated as a financing-market signal rather than an operating-margin signal.

Hippocratic AI has not publicly disclosed audited profitability. IPO timing is not confirmed unless explicitly stated in company or news sources.

The practical read is that the company remains private and is using capital to extend product, hiring, regulatory, deployment, or R&D capacity.

The funding profile suggests budget exists for tools tied directly to healthcare ai agents, security, compliance, infrastructure, hiring leverage, and customer deployment. Sellers should map pitches to a funded initiative rather than a generic productivity story.

The best outreach angle is to show how a product shortens deployment time, lowers risk, or improves measurable outcomes for the teams named in the leadership and product sections.